Changing the course of oncogenesis: The development of tyrosine kinase inhibitors

European Journal of Cancer, Supplement

Volumn 4, Issue 7, 2006, Pages 14-20

  Lacal, Juan Carlos ^a  

^a INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIINFECTIVE AGENT; CETUXIMAB; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; IMATINIB; IRINOTECAN; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER THERAPY; CARCINOGENESIS; CELL TRANSFORMATION; CLINICAL TRIAL; CYTOPLASM; HUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 33745285704     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcsup.2006.03.002     Document Type: Article

References (54)

1. Blume-Jensen P., and Hunter T. Oncogenic kinase signalling. Nature 411 6835 (2001) 355-365
2. Druker B.J. Imatinib as a paradigm of targeted therapies. Adv Cancer Res 91 (2004) 1-30
3. Manning G., Whyte D.B., Martinez R., Hunter T., and Sudarsanam S. The protein kinase complement of the human genome. Science 298 5600 (2002) 1912-1934
4. Dunn D.A. Mining the human kinome. Drug Discov Today 7 22 (2002) 1121-1123
5. Carlomagno F., and Santoro M. Receptor tyrosine kinases as targets for anticancer therapeutics. Curr Med Chem 12 15 (2005) 1773-1781
6. Riedel H., Massoglia S., Schlessinger J., and Ullrich A. Ligand activation of overexpressed epidermal growth factor receptors transforms NIH 3T3 mouse fibroblasts. Proc Natl Acad Sci USA 85 5 (1988) 1477-1481
7. Guy P.M., Platko J.V., Cantley L.C., Cerione R.A., and Carraway III K.L. Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc Natl Acad Sci USA 91 17 (1994) 8132-8136
8. Ciardiello F., and De Vita F. Epidermal growth factor receptor (EGFR) inhibitors in cancer therapy. Prog Drug Res 63 (2005) 93-114
9. Grunwald V., and Hidalgo M. Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst 95 12 (2003) 851-867
10. Yarden Y., and Sliwkowski M.X. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2 2 (2001) 127-137
11. Arteaga C.L. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 19 Suppl. 18 (2001) 32S-40S
12. Yarden Y. The EGFR family and its ligands in human cancer signalling mechanisms and therapeutic opportunities. Eur J Cancer 37 Suppl. 4 (2001) S3-S8
13. Wosikowski K., Silverman J.A., Bishop P., Mendelsohn J., and Bates S.E. Reduced growth rate accompanied by aberrant epidermal growth factor signaling in drug resistant human breast cancer cells. Biochim Biophys Acta 1497 2 (2000) 215-226
14. Knowlden J.M., Hutcheson I.R., Jones H.E., et al. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144 3 (2003) 1032-1044
15. Dickstein B., Valverius E.M., Wosikowski K., et al. Increased epidermal growth factor receptor in an estrogen-responsive, adriamycin-resistant MCF-7 cell line. J Cell Physiol 157 1 (1993) 110-118
16. Yu D., Liu B., Jing T., et al. Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol. Oncogene 16 16 (1998) 2087-2094
17. Dassonville O., Formento J.L., Francoual M., et al. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 11 10 (1993) 1873-1878
18. Ang K.K., Andratschke N.H., and Milas L. Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy. Int J Radiat Oncol Biol Phys 58 3 (2004) 959-965
19. Tsai C.M., Chang K.T., Li L., Perng R.P., and Yang L.Y. Interrelationships between cellular nucleotide excision repair, cisplatin cytotoxicity, HER-2/neu gene expression, and epidermal growth factor receptor level in non-small cell lung cancer cells. Jpn J Cancer Res 91 2 (2000) 213-222
20. Mayer A., Takimoto M., Fritz E., et al. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 71 8 (1993) 2454-2460
21. van Dam P.A., Vergote I.B., Lowe D.G., et al. Expression of c-erbB-2, c-myc, and c-ras oncoproteins, insulin-like growth factor receptor I, and epidermal growth factor receptor in ovarian carcinoma. J Clin Pathol 47 10 (1994) 914-919
22. Montgomery R.B., Guzman J., O'Rourke D.M., and Stahl W.L. Expression of oncogenic epidermal growth factor receptor family kinases induces paclitaxel resistance and alters beta-tubulin isotype expression. J Biol Chem 275 23 (2000) 17358-17363
23. Scambia G., Benedetti-Panici P., Ferrandina G., et al. Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy. Br J Cancer 72 2 (1995) 361-366
24. Twombly R. Failing survival advantage in crucial trial, future of Iressa is in jeopardy. J Natl Cancer Inst 97 4 (2005) 249-250
25. Shepherd F.A., Rodrigues P.J., Ciuleanu T., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353 2 (2005) 123-132
26. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351 4 (2004) 337-345
27. Bonner J.A., Harari P.M., Giralt J., et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. J Clin Oncol 22 Suppl. 14 (2004) 5507
28. Hortobagyi G.N. Trastuzumab in the treatment of breast cancer. N Engl J Med 353 16 (2005) 1734-1736
29. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353 16 (2005) 1673-1684
30. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353 16 (2005) 1659-1672
31. Toi M., Horiguchi K., Bando H., Saji S., and Chow L.W. Trastuzumab: updates and future issues. Cancer Chemother Pharmacol 56 Suppl. 7 (2005) 94-99
32. Radich J.P. Philadelphia chromosome-positive acute lymphocytic leukemia. Hematol Oncol Clin North Am 15 1 (2001) 21-36
33. Laurent E., Talpaz M., Kantarjian H., and Kurzrock R. The BCR gene and philadelphia chromosome-positive leukemogenesis. Cancer Res 61 6 (2001) 2343-2355
34. Daley G.Q., Van Etten R.A., and Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247 4944 (1990) 824-830
35. Lugo T.G., Pendergast A.M., Muller A.J., and Witte O.N. Tyrossine kinase activity and transformation potency of bcr-abl oncogene products. Science 247 4946 (1990) 1079-1082
36. Matsuguchi T., Salgia R., Hallek M., et al. Shc phosphorylation in myeloid cells is regulated by granulocyte macrophage colony-stimulating factor, interleukin-3, and steel factor and is constitutively increased by p210BCR/ABL. J Biol Chem 269 7 (1994) 5016-5021
37. Salgia R., Li J.L., Lo S.H., et al. Molecular cloning of human paxillin, a focal adhesion protein phosphorylated by P210BCR/ABL. J Biol Chem 270 10 (1995) 5039-5047
38. Tauchi T., Feng G.S., Shen R., et al. SH2-containing phosphotyrosine phosphatase Syp is a target of p210bcr-abl tyrosine kinase. J Biol Chem 269 21 (1994) 15381-15387
39. Ernst T.J., Slattery K.E., and Griffin J.D. p210Bcr/Abl and p160v-Abl induce an increase in the tyrosine phosphorylation of p93c-Fes. J Biol Chem 269 8 (1994) 5764-5769
40. Oda T., Heaney C., Hagopian J.R., et al. Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J Biol Chem 269 37 (1994) 22925-22928
41. Tauchi T., Boswell H.S., Leibowitz D., and Broxmeyer H.E. Coupling between p210bcr-abl and Shc and Grb2 adaptor proteins in hematopoietic cells permits growth factor receptor-independent link to ras activation pathway. J Exp Med 179 1 (1994) 167-175
42. Chai S.K., Nichols G.L., and Rothman P. Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients. J Immunol 159 10 (1997) 4720-4728
43. O'Brien S.G., Guilhot F., Larson R.A., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348 11 (2003) 994-1004
44. Bjorge J.D., Jakymiw A., and Fujita D.J. Selected glimpses into the activation and function of Src kinase. Oncogene 19 49 (2000) 5620-5635
45. Wiener J.R., Windham T.C., Estrella V.C., et al. Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. Gynecol Oncol 88 1 (2003) 73-79
46. Zhou H.J., Yan J., Luo W., et al. SRC-3 is required for prostate cancer cell proliferation and survival. Cancer Res 65 17 (2005) 7976-7983
47. Hirsch C.L., Smith-Windsor E.L., and Bonham K. Src family kinase members have a common response to histone deacetylase inhibitors in human colon cancer cells. Int J Cancer 118 3 (2005) 547-554
48. Dehm S.M., and Bonham K. SRC gene expression in human cancer: the role of transcriptional activation. Biochem Cell Biol 82 2 (2004) 263-274
49. Dehm S., Senger M.A., and Bonham K. SRC transcriptional activation in a subset of human colon cancer cell lines. FEBS Lett 487 3 (2001) 367-371
50. Irby R.B., Mao W., Coppola D., et al. Activating SRC mutation in a subset of advanced human colon cancers. Nat Genet 21 2 (1999) 187-190
51. Knight Z.A. Another possible mechanism of resistance to STI571. Blood 96 12 (2000) 4003-4005
52. Gorre M.E., Mohammed M., Ellwood K., et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293 5531 (2001) 876-880
53. le Coutre P., Tassi E., Varella-Garcia M., et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 95 5 (2000) 1758-1766
54. Shah N.P., Tran C., Lee F.Y., et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305 5682 (2004) 399-401